SEC Form 4 · accession 0001140361-17-019040
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Eric Davis
Officer — EVP, General Counsel
Period of report
Apr 28, 2017
Accepted (ET)
May 9, 2017 · 1:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 28, 2017 | A | 302 | $70.304 | A | 85,251 | D | |
| Common StockF2 | May 5, 2017 | M | 2,500 | $38.59 | A | 87,751 | D | |
| Common StockF2,F3 | May 5, 2017 | S | 2,500 | $100.341 | D | 85,251 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F2,F4 | $38.59 | May 5, 2017 | M | 2,500 | D | Nov 22, 2008 | May 21, 2018 | Common Stock | 2,500 | 39,844 | D |
Explanation of responses
- F1Represents shares acquired by the reporting person on April 28, 2017, pursuant to the issuer's Employee Stock Purchase Plan.
- F2Trade made pursuant to a 10b5-a plan executed on November 2, 2016.
- F3All shares were sold at the same price.
- F4Reflects the number of stock options outstanding after the transaction from this specific stock option grant.